Galectin Therapeutics is developing promising carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer, based on the company’s unique understanding of galectin proteins, key mediators of biologic function. They are leveraging extensive scientific and development expertise, as well as established relationships with external sources, to achieve cost effective and efficient development. The company is pursuing a clear development pathway to clinical enhancement and commercialization for their lead compounds in liver fibrosis and cancer. For more information, visit the company’s Web site at www.GalectinTherapeutics.com.

LD Micro is an internet-based newsletter that provides information on selected public companies to self-directed investors. It is anticipated that the two-day LD Micro Conference will be attended by more than 200 institutions focused on micro-cap and small-cap stocks. Last year, a record 580 people attended. For more information, please visit www.ldmicro.com.

Let us hear your thoughts below: